Huron consulting’s director James Roth sells $1.24 million in stock

James H. Roth, a director at Huron Consulting Group Inc. (NASDAQ:HURN), has recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Roth sold a total of 8,642 shares of Huron Consulting’s common stock on March 12, 2025. The shares were sold at prices ranging from $142.43 to $145.34, amounting to a total transaction value of approximately $1.24 million. The sale comes amid Huron’s impressive performance, with the stock delivering a 50% return over the past year and a 34% gain in the last six months.

The sales were executed under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for selling stocks, providing an affirmative defense against insider trading accusations. Following these transactions, Roth retains ownership of 64,921 shares directly and an additional 3,855 shares indirectly through a family LLC.

Investors often scrutinize insider transactions like these for insights into the company’s prospects, and such significant sales can attract attention. However, it’s important to note that insider sales can occur for various reasons unrelated to the company’s performance, such as personal financial planning.

In other recent news, Huron Consulting Group reported impressive fourth-quarter 2024 results, with earnings per share (EPS) of $1.90, surpassing the analyst estimate of $1.52. The company’s revenue for the quarter reached $399.31 million, exceeding the consensus estimate of $379.99 million. For the full year 2024, Huron’s revenue climbed to a record $1.49 billion, marking a 9.1% increase from the previous year. Looking ahead, the company provided guidance for 2025, projecting an EPS range of $6.80 to $7.60 and revenue between $1.58 billion and $1.66 billion.

Analysts have responded positively to Huron’s strong performance and future prospects. Truist Securities raised its price target for Huron to $180, maintaining a Buy rating, citing potential growth in healthcare and education sectors. Similarly, Benchmark analysts increased their price target to $165, also keeping a Buy rating, due to Huron’s robust earnings and favorable macroeconomic conditions. The company has also announced plans to host an Investor Day on March 25, 2025, to discuss its strategy and financial goals. These developments highlight Huron’s strong market position and potential for continued growth amidst evolving federal policies and market conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.